美国肥胖率在广泛使用GLP-1药物的驱动下,在2025年下降到37%,尽管获得治疗的机会仍然有限。 U.S. obesity rate fell to 37% in 2025, driven by widespread use of GLP-1 drugs, though access remains limited.

一项新的盖洛普调查显示,美国肥胖率在2025年下降到37%,低于2022年的39.9%,其中GLP-1减肥药物如半甲酸和甲酸被广泛使用为关键因素. A new Gallup survey shows the U.S. obesity rate dropped to 37% in 2025, down from a 2022 peak of 39.9%, with widespread use of GLP-1 weight-loss drugs like semaglutide and tirzepatide cited as a key factor. 这些注射用药的使用率在18个月内翻了一番以上,从5.8%的美国人增加到12.4%,特别是在50至64岁的成年人中,肥胖率下降了5.0%。 Usage of these injectable medications more than doubled in 18 months, rising from 5.8% to 12.4% of Americans, particularly among adults aged 50 to 64, where obesity rates fell by 5.0 percentage points. 妇女更有可能使用这些药物,并报告体重下降幅度更大。 Women are more likely to use the drugs and report greater weight loss. 尽管这些保险有效,但获得保险的机会仍然有限,因为许多保险公司计划停止覆盖这些药品,让病人每月支付500美元左右。 Despite their effectiveness, access remains limited, as many insurers plan to stop covering the drugs, leaving patients to pay about $500 monthly. 正在制作口头版本,但可负担性仍然是一个主要障碍。 Oral versions are in development, but affordability remains a major barrier. 调查还发现,糖尿病发病率创下了13.8%的纪录。 The survey also found a record-high diabetes rate of 13.8%.